Figure S1. LC-MS/MS analysis of VEGF165b-TMR digested with multiple proteases. (Relates to
). (a) Peptide coverage achieved by digestion with trypsin, LysC/GluC and elastase proteases. The N-terminal cysteine is marked in red. None of the other 14 residues presented in the VEGF165b protomer were labelled. Protein identity was confirmed by searching the MS/MS spectra using the Mascot search engine (Matrix Science Inc, Boston, USA) against a human database (SwissProt). The highest scoring hit was the VEGF sequence. (b) LC-MS/MS analysis of the peptide containing the N terminal cysteine (CDNAPMAEGGGQNHHEVVK) derived from VEGF165b-TMR (right panel) and VEGF165b (left panel) that were purified in the same manner and digested with trypsin protease. Retention times and mono-isotopic masses are given in Supplementary Table 1 Figure 1 ). Summary of binding affinities (pKi) of unlabelled VEGF-A isoforms determined from inhibition of the binding of VEGF165a-TMR, VEGF165b-TMR or VEGF121a-TMR to NanoLuc-VEGFR2 and NanoLuc-NRP1. Data are expressed as mean ± S.E.M determined from 5 independent experiments. ND = not determined due to lack of significant inhibition of binding with 30nM unlabelled VEGF isoform.
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